Erythropoietic Protoporphyria — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for erythropoietic protoporphyria. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
1
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Erythropoietic Protoporphyria

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Clivunel Inc 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating erythropoietic protoporphyria. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Scenesse
AFAMELANOTIDE
 Clivunel Inc 1 62 — 2033-01-20

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8334265 Scenesse method of use 62 2033-01-20

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8334265 Scenesse method of use 62 2033-01-20

Related